



**PE/Cy5 anti-mouse CD11c**

**Catalog # / Size:** 1186580 / 100 µg  
**Clone:** N418  
**Isotype:** Hamster IgG  
**Immunogen:** Mouse spleen dendritic cells  
**Reactivity:** Mouse  
**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.  
**Concentration:** 0.2



**Applications:**

**Applications:** Flow Cytometry  
**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 microg per 10<sup>6</sup> cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for other applications.



**Application Notes:** Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>3</sup>, immunohistochemical staining of acetone-fixed frozen sections<sup>3</sup>, and immunofluorescence microscopy<sup>5, 9</sup> (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections<sup>10</sup>).

C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and PE/Cy5 N418 (top) or PE/Cy5 Armenian hamster IgG isotype control (bottom)

**Application References:**

1. Granucci F, *et al.* 1997. *J. Immunol.* 159:1794.
2. Stokes RW, *et al.* 1998. *J. Immunol.* 160:5514.
3. Metlay JP, *et al.* 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, *et al.* 2006. *Cancer Research* 66:1169.
5. Chin RK, *et al.* 2006. *J. Immunol.* 177:290. (IF)
6. Cervantes-Barragan L, *et al.* 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, *et al.* 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)
8. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, *et al.* 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, *et al.* 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, *et al.* 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, *et al.* 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, *et al.* 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, *et al.* 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)

17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)  
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
- 

**Description:** CD11c is a 150 kD glycoprotein also known as  $\alpha_X$  integrin, CR4, and p150. CD11c forms a  $\alpha_X\beta_2$  heterodimer with  $\beta_2$  integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The  $\alpha_X\beta_2$  integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

**Antigen**  
**References:**

1. Barclay A, *et al.* 1997. *The Leukocyte Antigen Facts Book* Academic Press.
2. Springer TA. 1994. *Cell* 76:301.
3. Lopez-Rodriguez C, *et al.* 1996. *J. Immunol.* 156:3780.